Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Understanding Anti-Influenza Antiviral Drugs

Version 1 : Received: 28 July 2022 / Approved: 1 August 2022 / Online: 1 August 2022 (05:41:34 CEST)

How to cite: Ley, S. Understanding Anti-Influenza Antiviral Drugs. Preprints 2022, 2022080008 (doi: 10.20944/preprints202208.0008.v1). Ley, S. Understanding Anti-Influenza Antiviral Drugs. Preprints 2022, 2022080008 (doi: 10.20944/preprints202208.0008.v1).

Abstract

Antigenic drift in influenza strains allows viruses to avoid being fully suppressed by seasonal vaccines. As a result, public interest has led to increased scrutiny and reevaluation of anti-influenza antiviral drugs as possible solutions. Unfortunately, many anti-influenza drugs developed around the globe suffer from a lack of sufficient clinical trials, as well as a lack of toxicity data. This is especially true of Arbidol, a popularly used drug for the prevention and treatment of influenza strains in China and Russia. Neuraminidase inhibitors, which were developed in the United States, also fall victim to inconclusive clinical trials and adverse effects. Adamantanes, while proven to be effective in treating influenza A, are encountering rapid, widespread cross-resistance. Baloxavir marboxil, a newer anti-influenza medication, shows promise in treating acute uncomplicated influenza, and may avoid the development of resistance when coadministered with other antiviral drugs. This review explores the antivirals available for influenzas treatment at this time.

Keywords

influenza; antivirals; anti-influenza; influenza drugs; the flu

Subject

MEDICINE & PHARMACOLOGY, Pharmacology & Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.